Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial (Q36217472)

10 June 2018

title

Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial (English)

1 reference

10 June 2018

1 reference

4

1 reference

10 June 2018

Catherine M Viscoli

1

Catherine M Viscoli

1 reference

10 June 2018

Walter N. Kernan

10

Walter N Kernan

1 reference

10 June 2018

Robin Conwit

5

Robin Conwit

1 reference

10 June 2018

Karen L Furie

6

Karen L Furie

1 reference

10 June 2018

Mark P Gorman

7

Mark Gorman

1 reference

10 June 2018

Anne M Lovejoy

9

Anne M Lovejoy

1 reference

10 June 2018

Silvio E Inzucchi

2

Silvio E Inzucchi

1 reference

10 June 2018

IRIS Trial Investigators

11

IRIS Trial Investigators

1 reference

10 June 2018

author name string

Lawrence H Young

3

1 reference

10 June 2018

Michael A Kelly

8

1 reference

10 June 2018

language of work or name

English

0 references

publication date

1 March 2017

1 reference

10 June 2018

The Journal of Clinical Endocrinology and Metabolism

published in

1 reference

10 June 2018

volume

102

1 reference

10 June 2018

page(s)

914-922

1 reference

10 June 2018

issue

3

1 reference

10 June 2018

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Effects of diabetes drugs on the skeleton

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Risk of osteoporotic fractures following stroke in older persons

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Skeletal consequences of thiazolidinedione therapy

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

29 June 2018

Fractures after stroke.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve ty

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Fractures after stroke: frequency, types, and associations.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460686

Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus

22 September 2018

1 reference

12 December 2020

Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction

1 reference

12 December 2020

Rosiglitazone decreases bone mass and bone marrow fat

1 reference

12 December 2020

Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women

1 reference

12 December 2020

Acute and long-term increase in fracture risk after hospitalization for stroke

1 reference

12 December 2020

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus

1 reference

12 December 2020

Identifiers

DOI

10.1210/JC.2016-3237

1 reference

10 June 2018

PMCID

5460686

1 reference

10 June 2018

PubMed ID

27935736

1 reference

10 June 2018